New Risk • May 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swiss stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Announcement • Mar 26
Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026 Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026, at 11:00 W. Europe Standard Time. Major Estimate Revision • Mar 19
Consensus revenue estimates decrease by 11% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$225.0m to US$199.2m. EPS estimate unchanged from US$0.19 per share at last update. Biotechs industry in Switzerland expected to see average net income growth of 13% next year. Consensus price target up from CHF34.65 to CHF35.40. Share price fell 9.7% to CHF23.42 over the past week. Reported Earnings • Mar 15
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CHF0.068 (up from CHF0.10 loss in FY 2024). Revenue: CHF146.1m (up 93% from FY 2024). Net income: CHF2.46m (up CHF6.18m from FY 2024). Profit margin: 1.7% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 77%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has increased by 162% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 10
Kuros Biosciences AG Provides Earnings Guidance for the Year 2026-2028 Kuros Biosciences AG provided earnings guidance for the year 2026-2028. For the year, the Group expects at least 35% sales growth.
By 2028, the Group anticipates sales of USD 300 million to USD 330 million. New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Price Target Changed • Jan 17
Price target increased by 12% to CHF34.65 Up from CHF31.00, the current price target is an average from 2 analysts. New target price is 24% above last closing price of CHF28.04. Stock is up 26% over the past year. The company is forecast to post earnings per share of CHF0.20 next year compared to a net loss per share of CHF0.10 last year. Breakeven Date Change • Jan 01
Forecast breakeven date pushed back to 2026 The analyst covering Kuros Biosciences previously expected the company to break even in 2025. New forecast suggests the company will make a profit of CHF18.0m in 2026. Average annual earnings growth of 61% is required to achieve expected profit on schedule. Announcement • Oct 16
Kuros Biosciences AG Raises earnings Guidance for the Year 2025 Kuros Biosciences AG raised earnings guidance for the year 2025. For the year, Group is raising its sales guidance and now expects growth of at least 70% . Announcement • Sep 04
Kuros Biosciences Announces Board and Committee Changes Kuros Biosciences announced that Albert Arp has decided to resign from the Board of Directors with immediate effect for personal and professional reasons. Oliver Walker was appointed as Chair of the Audit and Risk Committee. Kimberley Elting was appointed as member of the Audit and Risk Committee and as member and Chair of the Compensation and Nomination Committee. Reported Earnings • Aug 14
First half 2025 earnings released: CHF0.051 loss per share (vs CHF0.01 loss in 1H 2024) First half 2025 results: CHF0.051 loss per share (further deteriorated from CHF0.01 loss in 1H 2024). Revenue: CHF63.5m (up 99% from 1H 2024). Net loss: CHF2.04m (loss widened CHF1.83m from 1H 2024). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 148% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 14
Kuros Biosciences Ag Provides Earnings Guidance for the Year 2025 and by 2027 Kuros Biosciences AG provided earnings guidance for the year 2025 and by 2027. For the year, the company expects robust sales growth of at least 60% in 2025.
Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction. Announcement • Aug 05
Kuros Biosciences Launches Magnetos MIS Delivery System by Completion of the First U.S. Cases Using the New Magnetos MIS Delivery System Kuros Biosciences announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System - a sterile, prefilled, single-use delivery system engineered for Minimally invasive Surgery in spine procedures. Following FDA 510(k) clearance of the MagnetOs MIS Delivery System in May, these first cases mark a significant milestone in expanding surgeon access to a more streamlined approach for graft delivery. Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. MagnetOs MIS builds on the proven science of MagnetOs and its proprietary NeedleGrip submicron surface technology, which harnesses the immune system to stimulate bone growth. It is engineered for precise delivery, surgical efficiency, and predictable fusion outcomes. Compared to delivering MagnetOs in a traditional, funnel-based system, MagnetOs MIS achieved graft placement three times faster, optimizing time in the operating room. The MIS system is supported by robust published clinical evidence for MagnetOs in cases where minimally invasive procedures and surgical site accessibility is crucial. In a retrospective study, MagnetOs achieved a 94.4% fusion rate across 36 levels treated in patients undergoing MIS and open transforaminal lumbar interbody fusions, where the majority of patients had comorbidities such as obesity, smoking, diabetes, or a previous spine surgery. These results build on previously published Level I prospective, randomized, controlled human clinical data demonstrating that MagnetOs achieved nearly twice the fusion rate of autograft in posterolateral fusion (79% vs. 47%). Additionally, and following the recent ANVISA approval of MagnetOs Granules, Kuros also announced that MagnetOs Putty now has been approved by the Brazilian regulatory authority, expanding the company's entry into the South American spine and orthopedic market. Announcement • Apr 15
Kuros Biosciences Ag Elects Kimberley Elting as A New Member of the Board of Directors Kuros Biosciences AG announced Kimberley Elting was elected as a new member of the Board of Directors. Announcement • Mar 26
Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025 Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025, at 11:00 W. Europe Standard Time. Reported Earnings • Mar 11
Full year 2024 earnings released: CHF0.12 loss per share (vs CHF0.38 loss in FY 2023) Full year 2024 results: CHF0.12 loss per share (improved from CHF0.38 loss in FY 2023). Revenue: CHF75.6m (up 125% from FY 2023). Net loss: CHF3.72m (loss narrowed 73% from FY 2023). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 115% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Feb 23
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 4.3% per year over the past 5 years. Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Announcement • Oct 10
Kuros Biosciences AG Provides Sales Guidance for the Second Half of 2024 Kuros Biosciences AG provided sales guidance for the second half of 2024. For the remainder of the second half of 2024, Kuros expects a similar seasonal sales pattern as in previous years, corresponding to around 57% to 60% of total annual sales. Reported Earnings • Aug 13
First half 2024 earnings released: CHF0.01 loss per share (vs CHF0.14 loss in 1H 2023) First half 2024 results: CHF0.01 loss per share (improved from CHF0.14 loss in 1H 2023). Revenue: CHF31.8m (up 148% from 1H 2023). Net loss: CHF211.0k (loss narrowed 96% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 71% per year, which means it is well ahead of earnings. New Risk • Aug 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 5.3% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Announcement • Apr 17
Kuros Biosciences AG Approves Board of Director and Committee Changes Kuros Biosciences AG at the Annual general meeting approved Board of director and committee changes. Albert Arp and Chris Fair (CEO) were elected as new members of the Board of Directors, Albert Arp was elected as a new member of the Compensation Committee. Scott Bruder did not stand for re-election as member of the board. Announcement • Mar 08
Kuros Biosciences AG to Report Fiscal Year 2023 Results on Mar 13, 2024 Kuros Biosciences AG announced that they will report fiscal year 2023 results on Mar 13, 2024 New Risk • Feb 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 0.1% per year over the past 5 years. Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Announcement • Jan 31
Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand Kuros Biosciences announced clearance of a 510(k) submission from the U.S. Food and Drug Administration related to its MagnetOs Granules. The Company also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty. The products are now commercially available through Vortek Spine Limited ("Vortek"), a high-tech orthopedic and biologics company specializing in healthcare solutions for surgeons and patients. This further expands the MagnetOs portfolio in terms of application and accessibility. Earlier in January, Kuros announced the FDA clearance of MagnetOs Easypack Putty for interbody use and MagnetOs Putty for standalone use in the posterolateral spine, meaning it can now be used without the need for autograft (patient's own bone). The availability of MagnetOs in New Zealand marks a significant milestone for Kuros and the local medical community since patients can now benefit from an advanced bone graft that improves the overall quality of care in orthopedic and spinal procedures. This benefit was further demonstrated with recent level 1 clinical data in which MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population, of which 20% were current smokers. Announcement • Nov 29
Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal Cages Kuros Biosciences announced that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA). As a result, it can now be used in any interbody space (cervical, thoracic, lumbar); and in any cage approved for use with a bone void filler. With interbody cages being used in almost half of the estimated 1.5 million instrumented spinal fusion procedures conducted annually in the USA, this news is especially significant for surgeons. MagnetOs Flex Matrix is uniquely well suited to interbody applications. Due to its excellent granule retention, it stays strong yet flexible even when wet - for easy placement either through a funnel or packed directly into any cage, of any size. MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having already been cleared by the FDA for use in posterolateral fusions. Due to its unique fibrillar and flexible structure, this open matrix bone graft promotes bone growth even in soft tissue by optimizing the effect of Kuros' established NeedleGrip surface technology. Reported Earnings • Mar 16
Full year 2022 earnings released: CHF0.43 loss per share (vs CHF0.23 loss in FY 2021) Full year 2022 results: CHF0.43 loss per share (further deteriorated from CHF0.23 loss in FY 2021). Revenue: CHF18.0m (up 30% from FY 2021). Net loss: CHF14.6m (loss widened 94% from FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Oliver Walker was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 16
Kuros Biosciences AG has completed a Follow-on Equity Offering in the amount of CHF 6 million. Kuros Biosciences AG has completed a Follow-on Equity Offering in the amount of CHF 6 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 3,750,000
Price\Range: CHF 1.6
Transaction Features: Subsequent Direct Listing Announcement • Aug 24
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones Kuros Biosciences announced that its MagnetOs bone graft has successfully achieved three key clinical and commercial milestones, with completion of enrolment in the PARTNER clinical trial, the first patient treated with MagnetOs Flex Matrix and reaching a total of 10,000 patients treated with MagnetOs worldwide. PARTNER is the first of five Level 1 randomized controlled trials for MagnetOs to be fully enrolled and conducted under the umbrella research program known as Project Fusion, which compares MagnetOs to the gold standard of autograft bone. A total of 30 patients with leg pain and/or back pain, requiring up to three-level instrumented posterolateral lumbar fusion (L2 - S1), were included in the study and an interim analysis will be performed once the first 15 patients have completed their Month 6 visit with available measurements for the endpoints. The first patient was treated with MagnetOs Flex Matrix, which opens up an opportunity for the 62% of all U.S. spine surgeons who routinely mix their bone graft of choice with bone marrow aspirate, by Dr. Terrence Crowder at the Arizona Spine and Joint Hospital. MagnetOs Flex Matrix was mixed with autograft and used in a posterolateral fusion over the facets in a patient with degenerative disc disease. MagnetOs Flex Matrix is a new open matrix bone graft with a unique fibrillar and flexible structure that optimizes the effect of Kuros’ established NeedleGrip surface technology and is extremely convenient to use with strength and flexibility. Reported Earnings • Aug 11
First half 2022 earnings released: CHF0.11 loss per share (vs CHF0.003 loss in 1H 2021) First half 2022 results: CHF0.11 loss per share (down from CHF0.003 loss in 1H 2021). Revenue: CHF10.4m (up 15% from 1H 2021). Net loss: CHF3.70m (loss widened CHF3.60m from 1H 2021). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Announcement • Jun 09
Kuros Biosciences AG, Annual General Meeting, Jun 08, 2022 Kuros Biosciences AG, Annual General Meeting, Jun 08, 2022. Agenda: To approve the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2021 and take note of the Reports of the Auditors; to consider appropriation of the Annual Results and approved the compensation for the members of the Board of Directors and the Executive Committee; to consider board changes; and to consider other matters. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Oliver Walker was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 22
Kuros Biosciences’S Magnetos Flex Matrix Receives Clearance by U.S. Food and Drug Administration for Spinal Indications Kuros Biosciences announced that its MagnetOs Flex Matrix has been cleared by the U.S. Food and Drug Administration (FDA) as a bone void filler for use in the posterolateral spine. MagnetOs Flex Matrix is a new open matrix bone graft with a unique fibrillar and flexible structure that optimizes the effect of Kuros' established pro-healing NeedleGripTM surface technology for more predictable fusion. U.S. spine surgeons routinely mix their bone graft of choice with bone marrow aspirate and the MagnetOs Flex Matrix allows them to reap the benefits of MagnetOs' NeedleGripTM surface technology while continuing with their routine perioperative practice. The clearance of MagnetOs Flex Matrix is the third new FDA clearance for the MagnetOs product family within the last 7 months and follows existing FDA clearances for the use of MagnetOs Granules, MagnetOs Putty and MagnetOs Easypack Putty in the spine. MagnetOs Flex Matrix is convenient to use with excellent granule retention. It has extremely high wickability and absorbs up to ten times as much BMA as other bone grafts, with the potential to deliver even greater bone healing1. It remains strong but flexible even when wet so it can be torn, molded and folded to fill bony spaces in any way required. Reported Earnings • Mar 18
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: CHF0.23 loss per share (up from CHF0.47 loss in FY 2020). Revenue: CHF13.8m (up 242% from FY 2020). Net loss: CHF7.54m (loss narrowed 35% from FY 2020). Revenue exceeded analyst estimates by 104%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Feb 03
Kuros Biosciences Ag Announces Its Magnetos Granules Cleared by FDA for Expanded Spinal Indications Kuros Biosciences announced that its MagnetOs Granules has been cleared by the U.S. Food and Drug Administration (FDA) for expanded indications in the spine, making it only the second-ever bone graft to achieve clearance for standalone use in the spine based on human clinical data. The FDA clearance was attained using radiographic data, clinical outcomes and safety data from 50 patients who were enrolled in a Level 1 randomized controlled multicenter trial in which MagnetOs Granules were compared head-to-head against autograft, the gold standard for posterolateral fusion. The clearance for standalone use proves MagnetOs to be an augmented graft that can be used in place of, as well as in combination with, autograft bone. Standalone use requires the body to rely on the implanted bone graft product and not on combined autograft from the patient, which means the bar for proving standalone efficacy is higher than for bone graft extender efficacy. Contrary to MagnetOs Granules, very few bone grafts are supported by Level 1 evidence from a randomized controlled trial. For instance, the current market-leading synthetic is supported by only one Level 1 pilot study, in which 20 patients were treated as opposed to the 50 patients treated in Kuros’s multicenter trial. Across all published studies for the market-leading synthetic, 90% of patients were from studies by a single investigator, and conducted at a single clinical site, and 96% of all patients were from non-randomized Level III/IV studies which provide a lower evidence base for clinical decision-making than Level I studies. The data package used in the FDA submission is the first Level 1 data to emerge from the Company's Project Fusion. Announcement • Jan 20
Kuros Biosciences Publishes First-In-Human Clinical Data for Fibrin-PTH in Treatment of Open Tibial Shaft Fractures Kuros Biosciences announced the publication of first-in-human data from a Phase II trial of Fibrin-PTH (KUR-113) in open tibial shaft fractures in The Journal of Bone and Joint Surgery (JBJS), the leading peer-reviewed orthopedic research journal. The article, entitled 'Novel Parathyroid Hormone-Based Bone Graft, KUR-113, in Treatment of Acute Open Tibial Shaft Fracture', outlined results from the multicenter, randomized, controlled dose-finding study with 200 patients who had an open tibial shaft fracture secondary to trauma. The healing rate at six months post-surgery for intend-to-treat patients was 76%, 80% and 69% for patients receiving the low, medium and high doses of Fibrin-PTH administered on top of standard of care respectively. This compared with 65% for those receiving standard of care alone. The primary endpoint was met in the mid-dose group, with a significantly higher prevalence of healing at six months than the control group. Announcement • Sep 29
Kuros Biosciences to Showcase New Magnetos Products At Nass 2021 Annual Meeting Kuros Biosciences announced that it will showcase new products in the MagnetOs range at the 36th Annual Meeting of the North American Spine Society (NASS), being held in Boston from September 29 to October 2, 2021. Kuros is expanding its current MagnetOs Putty range to include a new 2.5cc unit that is ideal fobr filling gaps in the spine during posterior cervical fusion procedures. The company will also demonstrate its new MagnetOs Easypack Putty, which was recently granted 510(k) clearance by the US Food and Drug Administration (FDA). In addition, Kuros will present data for a new formulation of MagnetOs that includes a collagen carrier, and which is being designed for surgeons who prefer to mix their bone graft with blood or bone marrow aspirate. Announcement • Jun 23
Kuros Biosciences Announces Publication of Data on Magnetos in eCM Journal Linking Moa to Enhanced Predictable Bone Regeneration Kuros Biosciences announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on preclinical re-search in the musculoskeletal field, on the mechanism of action of its MagnetOs bone graft. The paper describes how immunomodulation by bone grafts with submicron topographical fea-tures translates to enhanced bone regeneration and successful spinal fusion. This is the first and only fully-translational peer-reviewed article for a bone graft material, describing evidence of its performance from benchtop to the clinic. Kuros helps patients live fuller, more active lives by giving surgeons the technology they need to eliminate non-unions. MagnetOs bone graft achieves this with a unique surface design proven to unlock the untapped power of the body's immune system by growing new bone throughout the graft - for more predictable fusions. The eCM Journal article highlighted the following key points: Evidence that submicron needle-shaped surface features accelerate osteoinduction by calcium phosphate in vivo. In vitro studies demonstrating that upregulation of pro-healing M2 macrophages occurs on submicron needle-shaped topography. An in vivo study demonstrating that M2 macrophage upregulation by submicron needle-shaped topography precedes osteoinductive bone formation. In vivo studies of calcium phosphate with submicron topography in clinically-relevant spi-nal fusion models, demonstrating equivalence with autograft and superiority to other synthetic bone grafts. Results of a clinical study in a in real-life cohort, in which calcium phosphate with submi-cron topography was successfully used in 52 lumbar and 25 cervical fusion patients, reaching 12-month fusion rates of 97% and 94% of treated levels, respectively. Reported Earnings • Mar 21
Full year 2020 earnings released: CHF0.47 loss per share (vs CHF0.71 loss in FY 2019) Full year 2020 results: Net loss: CHF11.5m (loss widened 2.4% from FY 2019). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • Mar 19
Kuros Biosciences AG to Complete the Phase II Clinical Study of Fibrin-PTH in Spine Kuros Biosciences AG to complete the Phase II clinical study of Fibrin-PTH in spine, with the first (interim) data expected to be available by early 2022 and full (1-yr endpoint) data in the second half of 2022. Announcement • Mar 03
Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe Kuros Biosciences announced that it has signed sales and distribution agreements for MagnetOs bone graft, covering the Netherlands, Switzerland, Austria, and Finland. These add to an existing agreement in the United Kingdom and Ireland. Kuros has signed a sales agency agreement with Lubbers Medical BV giving Lubbers non-exclusive rights to sell MagnetOs in the Netherlands, effective fourth quarter 2020. Kuros has signed exclusive stocking distributor agreements for Switzerland and Austria with Orthocontor AG and Amacord GmbH, respectively, both effective First Quarter 2021. Is New 90 Day High Low • Jan 21
New 90-day high: CHF2.30 The company is up 18% from its price of CHF1.96 on 23 October 2020. The Swiss market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period. Is New 90 Day High Low • Oct 16
New 90-day low: CHF2.10 The company is down 6.0% from its price of CHF2.24 on 17 July 2020. The Swiss market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 22% over the same period.